SNMMI is continuing to review the proposed NCD and will be submitting comments to CMS. Our preliminary thoughts are that CMS’s decision to cover Alzheimer’s therapy under CED is an incomplete solution rather than a productive resolution that would allow widespread and equitable patient access to monoclonal antibody therapy or clinical trials of that treatment. We hope CMS will change its position in its final decision, due in April 2022. The Society seeks broad national coverage of the scans either by a positive NCD or at Medicare Administrative Contractor (MAC) discretion.
About the Society of Nuclear Medicine and Molecular Imaging
Ad Statistics
Times Displayed: 22279
Times Visited: 445 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
SNMMI’s members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice.
Back to HCB News
